Levomethadone Hydrochloride Molteni (Levomethadone Hydrochloride)

Levomethadone Hydrochloride acts on the opioid system to treat conditions related to opioid use and pain.

• Opioid dependence: helps maintain abstinence and reduces cravings during maintenance therapy.
• Opioid withdrawal: alleviates withdrawal symptoms and facilitates a smoother detoxification process.
• Chronic pain: provides opioid analgesia for patients requiring long‑term pain control.

• Levomethadone Hydrochloride is a potent agonist at the mu‑opioid receptor, producing analgesia and suppressing opioid withdrawal symptoms. It also antagonizes NMDA receptors, which may reduce opioid tolerance and modulate pain pathways. The combined activity results in both central analgesic effects and mitigation of withdrawal phenomena.

Levomethadone Hydrochloride may cause a range of adverse reactions.

Common Side Effects

• Constipation: reduced bowel motility leading to hard stools.
• Nausea: feeling of sickness that may be mild to moderate.
• Drowsiness: increased sleepiness or reduced alertness.
• Dry mouth: decreased salivation causing oral discomfort.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be life‑threatening.
• QT interval prolongation: potential cardiac arrhythmia risk.
• Severe hypotension: marked drop in blood pressure.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.

Levomethadone Hydrochloride requires careful monitoring and specific safety measures.

• Assess opioid tolerance: confirm patient has prior opioid exposure before initiating therapy.
• Monitor respiratory function: watch for signs of slowed breathing, especially during dose adjustments.
• Avoid concurrent CNS depressants: limit use with benzodiazepines or barbiturates.
• Use caution in hepatic impairment: liver dysfunction may alter drug metabolism.
• Use caution in patients with cardiac conduction disorders: QT prolongation risk.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Levomethadone Hydrochloride can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid)

• Benzodiazepines and other CNS depressants: increased risk of respiratory depression.
• MAO inhibitors: potential for severe hypotension and serotonin syndrome.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise levomethadone plasma levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
• Serotonergic agents (e.g., SSRIs, tramadol): risk of serotonin syndrome.
• Alcohol: can enhance sedative and respiratory effects.